Figure 8c:

Development of tumoral cavitation in a 64-year-old man with stage IV adenocarcinoma of the lung treated with bevacizumab, carboplatin, and paclitaxel. (a) Contrast-enhanced CT scan of the chest demonstrated a solid mass in the right upper lobe. The patient was subsequently treated with bevacizumab, carboplatin, and paclitaxel. (b) Follow-up CT at 1.5 months from the initiation of therapy demonstrated a development of tumoral cavitation within the mass. Since the cavity does not contain viable tumor cells, simply measuring the longest diameter of the mass may underestimate the response to treatment, representing one of the pitfalls of RECIST. (c) Follow-up CT at 4 months of therapy demonstrated further cavitation of the tumor occupying the majority of the tumor, with irregular and nodular components along the wall of the tumor.